These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 19049901)

  • 41. Drug-likeness and increased hydrophobicity of commercially available compound libraries for drug screening.
    Zuegg J; Cooper MA
    Curr Top Med Chem; 2012; 12(14):1500-13. PubMed ID: 22827520
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Similarity in drugs: reflections on analogue design.
    Wermuth CG
    Drug Discov Today; 2006 Apr; 11(7-8):348-54. PubMed ID: 16580977
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Computational identification of bioactive natural products by structure activity relationship.
    Zhou X; Li Y; Chen X
    J Mol Graph Model; 2010 Aug; 29(1):38-45. PubMed ID: 20488738
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Selective optimization of side activities: another way for drug discovery.
    Wermuth CG
    J Med Chem; 2004 Mar; 47(6):1303-14. PubMed ID: 14998318
    [No Abstract]   [Full Text] [Related]  

  • 45. Development of a method for evaluating drug-likeness and ease of synthesis using a data set in which compounds are assigned scores based on chemists' intuition.
    Takaoka Y; Endo Y; Yamanobe S; Kakinuma H; Okubo T; Shimazaki Y; Ota T; Sumiya S; Yoshikawa K
    J Chem Inf Comput Sci; 2003; 43(4):1269-75. PubMed ID: 12870920
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of chemical libraries for their druggability.
    Sirois S; Hatzakis G; Wei D; Du Q; Chou KC
    Comput Biol Chem; 2005 Feb; 29(1):55-67. PubMed ID: 15680586
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Scopy: an integrated negative design python library for desirable HTS/VS database design.
    Yang ZY; Yang ZJ; Lu AP; Hou TJ; Cao DS
    Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32892221
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Working with small molecules: rules-of-thumb of "drug likeness".
    Zhang MQ
    Methods Mol Biol; 2012; 803():297-307. PubMed ID: 22065233
    [TBL] [Abstract][Full Text] [Related]  

  • 49. FOG: Fragment Optimized Growth algorithm for the de novo generation of molecules occupying druglike chemical space.
    Kutchukian PS; Lou D; Shakhnovich EI
    J Chem Inf Model; 2009 Jul; 49(7):1630-42. PubMed ID: 19527020
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recent trends in library design: 'rational design' revisited.
    Schnur DM
    Curr Opin Drug Discov Devel; 2008 May; 11(3):375-80. PubMed ID: 18428091
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Distance phenomena in high-dimensional chemical descriptor spaces: consequences for similarity-based approaches.
    Rupp M; Schneider P; Schneider G
    J Comput Chem; 2009 Nov; 30(14):2285-96. PubMed ID: 19266481
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Data mining a small molecule drug screening representative subset from NIH PubChem.
    Xie XQ; Chen JZ
    J Chem Inf Model; 2008 Mar; 48(3):465-75. PubMed ID: 18302356
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structural Similarities between Some Common Fluorophores Used in Biology, Marketed Drugs, Endogenous Metabolites, and Natural Products.
    O'Hagan S; Kell DB
    Mar Drugs; 2020 Nov; 18(11):. PubMed ID: 33238416
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Designing active template molecules by combining computational de novo design and human chemist's expertise.
    Lameijer EW; Tromp RA; Spanjersberg RF; Brussee J; Ijzerman AP
    J Med Chem; 2007 Apr; 50(8):1925-32. PubMed ID: 17367122
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The application of in silico drug-likeness predictions in pharmaceutical research.
    Tian S; Wang J; Li Y; Li D; Xu L; Hou T
    Adv Drug Deliv Rev; 2015 Jun; 86():2-10. PubMed ID: 25666163
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bioinformatics and cheminformatics: where do the twain meet?
    Sukumar N; Krein M; Breneman CM
    Curr Opin Drug Discov Devel; 2008 May; 11(3):311-9. PubMed ID: 18428084
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug repositioning for enzyme modulator based on human metabolite-likeness.
    Lee YH; Choi H; Park S; Lee B; Yi GS
    BMC Bioinformatics; 2017 May; 18(Suppl 7):226. PubMed ID: 28617219
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Can 'Bacterial-Metabolite-Likeness' model improve odds of 'in silico' antibiotic discovery?
    Cherkasov A
    J Chem Inf Model; 2006; 46(3):1214-22. PubMed ID: 16711741
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular properties that influence oral drug-like behavior.
    Lajiness MS; Vieth M; Erickson J
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):470-7. PubMed ID: 15338956
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A minimalist fragment approach for the design of natural-product-like synthetic scaffolds.
    Genis D; Kirpichenok M; Kombarov R
    Drug Discov Today; 2012 Nov; 17(21-22):1170-4. PubMed ID: 22659098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.